Form 8-K - Current report:
SEC Accession No. 0001396814-22-000024
Filing Date
2022-03-15
Accepted
2022-03-15 08:02:29
Documents
15
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcrx-20220315.htm   iXBRL 8-K 34293
2 EX-99.1 pcrx-february2022revenuepr.htm EX-99.1 30438
3 PACIRA BIOSCIENCES LOGO pacirabiosciencesa01a.jpg GRAPHIC 27796
  Complete submission text file 0001396814-22-000024.txt   281280

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcrx-20220315.xsd EX-101.SCH 2163
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pcrx-20220315_def.xml EX-101.DEF 14956
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcrx-20220315_lab.xml EX-101.LAB 29116
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcrx-20220315_pre.xml EX-101.PRE 15553
9 EXTRACTED XBRL INSTANCE DOCUMENT pcrx-20220315_htm.xml XML 12009
Mailing Address 5 SYLVAN WAY SUITE 300 PARSIPPANY NJ 07054
Business Address 5401 WEST KENNEDY BOULEVARD SUITE 890 TAMPA FL 33609 813-553-6680
Pacira BioSciences, Inc. (Filer) CIK: 0001396814 (see all company filings)

EIN.: 510619477 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35060 | Film No.: 22739161
SIC: 2834 Pharmaceutical Preparations